Sotatercept (WINREVAIR™) by Merck has been FDA approved for the treatment of pulmonary arterial hypertension (PAH), a condition with a high risk of heart failure. Sotatercept disrupts signaling pathways by sequestering activin, a protein that promotes growth in the pulmonary arteries. ACVR2A, the target of Sotatercept, also plays a crucial role in various diseases beyond PAH, making it a promising target for drug development. Sino Biological provides essential tools for PAH research, including recombinant proteins, antibodies, and growth factors, supporting researchers in developing novel treatments to improve patient outcomes in PAH and other diseases.
Source link
An ActRIIA fusion protein got FDA approved for PAH treatment
